RT Journal Article
SR Electronic
T1 MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 311
OP 328
DO 10.2967/jnumed.108.058651
VO 51
IS 2
A1 Sgouros, George
A1 Roeske, John C.
A1 McDevitt, Michael R.
A1 Palm, Stig
A1 Allen, Barry J.
A1 Fisher, Darrell R.
A1 Brill, A. Bertrand
A1 Song, Hong
A1 Howell, Roger W.
A1 Akabani, Gamal
A1 In collaboration with the SNM MIRD Committee: Wesley E. Bolch, A. Bertrand Brill, Darrell R. Fisher, Roger W. Howell, Ruby F. Meredith, George Sgouros (Chair), Barry W. Wessels, and Pat B. Zan
YR 2010
UL http://jnm.snmjournals.org/content/51/2/311.abstract
AB The potential of α-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of α-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with α-particle emitters. Although α-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted α-particle emitter therapy and to provide guidance and recommendations for human α-particle emitter dosimetry.